PBC
A Stepwise Approach to Patients With Abnormal Liver Enzymes
Abnormal liver tests are a common occurrence in the United States.
JUNE 5, 2025
Expert Picks From The Liver Meeting 2024
In this second part of a two-part series, Ashwani Singal, MD, MS, discusses abstracts on treatment of severe ...
MAY 22, 2025
New PBC Drugs Show Sustained Efficacy in Extension Studies
Elafibranor and seladelpar, both recently approved by the FDA for treatment of PBC, showed prolonged efficacy and ...
MAY 20, 2025
Elafibranor Significantly Improves Prognosis For Patients With PBC, Study Finds
Elafibranor is predicted to increase transplant-free survival and reduce mortality over 15 years in patients with ...
FEBRUARY 13, 2025
Accelerated FDA Approval Ushers In New Era in Primary Biliary Cholangitis Treatment
The FDA’s recent accelerated approval of seladelpar for the treatment of PBC is a critical advancement for ...
JANUARY 13, 2025
FDA Issues Serious Liver Injury Warning for Obeticholic Acid
The FDA has issued a warning of serious liver injury for patients taking obeticholic acid for primary biliary ...
DECEMBER 16, 2024
Obeticholic Acid Proves Its Mettle As Second-Line Therapy for PBC
Patients with primary biliary cholangitis treated with obeticholic acid as second-line therapy within the POISE ...
NOVEMBER 29, 2022
Promising New Second-Line Therapy for Primary Biliary Cholangitis Emerges, More Data to Come
Seladelpar could eventually become the standard second-line treatment for primary biliary cholangitis, according to ...
MARCH 9, 2021
Pipeline Rich for Bile Acid Drugs
Arlington, Va.—Hepatologists treating patients with cholangiopathies have had few options. But that might be ...
OCTOBER 3, 2018
Fibrates Gaining Favor for PBC
Arlington, Va.—With only two treatment options for primary biliary cholangitis, some hepatologists have cast ...
AUGUST 21, 2018
